Ovarian Cancer

Audra Moran, CEO & President of the Ovarian Cancer Research Fund Alliance discusses the Ovarian Cancer National Conference.

David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors.

For women with platinum-sensitive, high-grade ovarian, fallopian tube or primary peritoneal cancer, an improved progression-free survival (PFS) was seen for those who took Rubraca (rucaparib) as a maintenance therapy, compared to placebo, according to the phase 3 ARIEL3 trial.

For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.

Strategies from expert oncology dieticians can help patients to eat an appropriate diet and maintain a healthy weight during and after treatment for ovarian cancer.

Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.

Mark Gibbons of Caregiver Action Network discusses the emotions caregivers to patients with ovarian cancer may have.

Opening the 20th Annual Ovarian Cancer National Conference in Chicago, John Moroney, M.D., underscored the challenges that remain in the early detection and treatment of ovarian cancer, but also the tremendous hope that resides in robust clinical trial research.

Nita Karnik Lee, MD, MPH, of The University of Chicago Medicine, discusses what patients with ovarian cancer should know about when entering survivorship.

Mark Gibbons, senior director of external programs with the nonprofit Caregiver Action Network, explains the importance of caregivers taking care of themselves while at the Ovarian Cancer National Conference.

Jennifer Lane-Riefler, MCHES, CFm, Executive Director of Cancer Services of Grant County, discusses the financial assistance opportunities available for patients with ovarian cancer.

The future of treating ovarian cancer may lie in combinations of immunotherapy plus PARP inhibitors, says Samir N. Khleif, M.D.

A recent study examined how age plays a factor in cancer risk for women with the BRCA1 or BRCA2 genetic mutation.

Superior progression-free survival (PFS) was seen in patients with ovarian cancer who previously had a partial response (PR) to platinum-based therapy when they took Zejula (niraparib). This response was seen in patients with or without germline BRCA mutations, according to data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

The idea of interfering with DNA’s self-repair capabilities has been at the heart of this decade’s progress in treating ovarian cancer, and the focus now is on combining PARP inhibitors with other types of therapies.

Sharon Bober, PhD, discusses how patients can ask their doctors about sexual health.

Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.

The program XRAYS is a resource to help patients, survivors and their loved ones make sense of the articles on hereditary cancer they see in the mainstream media and via social media platforms.

The uncertainty that arises from an ovarian cancer diagnosis can be very stressful. A recent study examined these feelings that many women with the disease are experiencing.

A recent study found Avastin to be more effective in treating certain types of ovarian cancers.

Black and Latina women with ovarian cancer were less likely than white women to enroll in hospice care within the last 30 days.

Ovarian cancer is rare, and receives less research funding than some other cancers.

The investigational compound targets overexpressed folate receptor-alpha.

After eight years with no new treatments for ovarian cancer, PARP inhibitors and anti-angiogenics are benefiting patients.

Shana Wingo, M.D., discussed advancements being made in the field of surgery for patients with gynecologic cancers.

A recent study examined common co-morbidities, such as diabetes, heart disease and hypertension, and their effects on ovarian cancer survival.